InvestorsHub Logo
Followers 67
Posts 2521
Boards Moderated 1
Alias Born 01/29/2018

Re: None

Thursday, 09/12/2019 7:50:06 PM

Thursday, September 12, 2019 7:50:06 PM

Post# of 93
CANAQUEST MEDICAL CORP announces Award of a
THC and CBD Research & Development at prestigious universities is the primary factor for the development of the Company’s Products.
TORONTO – September 11, 2019 - CANAQUEST MEDICAL CORP (OTC Markets: “CANQF”) (the "Company" or “CanaQuest”), a company developing proprietary health products and nutraceuticals utilizing cannabinoid and botanical oil extracts,
“As a licence holder under the Cannabis Regulations, our company can now target the introduction of our first proprietary Cannabis THC and Botanical formulation, MentabinolTM after December 17th., 2019.” Paul Ramsay, Co-Founder and President of CanaQuest stated. “
Licence as permitted under the Health Canada Cannabis Act, through its wholly
owned subsidiary, ADC BioMedical Corp.
Licence is a foundation for the company to begin domestic and international sales of our
Proprietary Cannabis and Botanical formulated products.
Under the proposed Health Canada Amendment for Cannabis Edibles Regulations, our
products will be included and licenced for sale as of December 17th, 2019.
through its wholly-owned subsidiary, ADC BioMedical
Corp., has obtained a cannabis purchase/sales licence, with a provision to apply for import/export permits
for cannabis as permitted under the Health Canada Cannabis Act.
The research and pre-clinical
trials have positioned us to introduce our novel THC formulation to provide a better alternative for recreational and medicinal consumers today. Our goal is to make all consumers of THC products (recreational or medical), who are concerned about the short term and long term negative psychotic
effects of THC, aware that our products exist. There is
discovery.” Ramsay further stated.
13 years of research that has led to this amazing
The company’s competitive advantage comes from Intellectual Property developed under its sponsored research contract with Western University. Through this partnership with Dr. Laviolette, a scientific veteran with over 13 years of research in the field of mental health and cannabis, plus a dedicated scientific team of 12 scientists and Western University, CanaQuest has a definitive competitive advantage in developing Research and Science based formulations for better THC and CBD experiences. The completed pre-clinical trials at the Western University lab has demonstrated exciting results and has put the Company in a position to introduce CanaQuest’s novel THC formulation at the inception of the Edible and Extract marketplace. Additionally, the scientific data and the beneficial results of our proprietary CBD-based formulation is in the final stage and we anticipate introduction of this new formulation into the marketplace in the very near future.
http://www.schulich.uwo.ca/anatomy/people/bios/faculty/laviolette_steve.html
Cannabis Purchase/Sales